# RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX

> **NCT01049620** · PHASE1 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 40 (actual)

## Conditions studied

- Advanced Gastric Cancer

## Interventions

- **DRUG:** RAD001, Capecitabine, Oxaliplatin

## Key facts

- **NCT ID:** NCT01049620
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2011-07
- **Final completion:** 2013-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01049620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01049620, "RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01049620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*